Almirall, S.A. (LBTSF) Stock Analysis

Almirall, S.A. (LBTSF) Healthcare & Pipeline Overview

Almirall, S.A. is a Barcelona-based biopharmaceutical company focused on dermatology, developing and commercializing treatments for various skin conditions across Europe, the US, and international markets. With a robust portfolio including Ilumetri and Klisyri, the company also engages in strategic collaborations to expand its therapeutic reach beyond its core dermatological expertise.

What Is the Investment Thesis for LBTSF?

Almirall, S.A. operates as a specialized biopharmaceutical entity with a market capitalization of $3.34B, primarily focused on dermatology. The company's investment profile is characterized by a P/E ratio of 30.91, reflecting market expectations for future growth, and a strong gross margin of 67.1%, indicating efficient production and pricing power for its specialized products. A profit margin of 3.8% suggests room for operational efficiency improvements. Growth catalysts include the ongoing development and commercialization of its established dermatology portfolio, such as Ilumetri and Klisyri, and the potential for new product approvals from its pipeline. Strategic collaborations with partners like Eli Lilly and Company and WuXi Biologics are crucial for expanding its R&D capabilities and market reach. However, the company's listing on the OTC Other tier presents potential liquidity risks for investors, and its beta of 0.17 indicates low volatility relative to the broader market. The 1.34% dividend yield offers a modest return, while the company's ability to navigate regulatory decisions and competitive pressures in the specialty drug market will be key value drivers.

Based on FMP financials and quantitative analysis

LBTSF Key Highlights

Market capitalization of $3.34B, reflecting its substantial presence within the specialty pharmaceutical sector.

• Price-to-Earnings (P/E) ratio of 45.40, indicating investor confidence in its future earnings potential relative to current profitability.
• Gross Margin of 67.1%, demonstrating robust profitability from its product sales before considering operating expenses.
• Profit Margin of 3.8%, representing the company's net income as a percentage of its revenue, highlighting its overall financial efficiency.
• Dividend Yield of 1.34%, providing a consistent return to shareholders through regular distributions.

Who Are LBTSF's Competitors?

LBTSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are LBTSF's Key Strengths?

Specialized focus and established expertise in dermatology with a diverse product portfolio.

• Strong gross margin of 67.1%, indicating efficient cost management and pricing power for its products.
• Extensive network of strategic collaborations and alliances enhancing R&D capabilities and market reach.
• Global operational presence across Europe, the United States, and other international markets.
• Diversified offerings beyond dermatology into other therapeutic areas, providing broader market exposure.

What Are LBTSF's Weaknesses?

Relatively low profit margin of 3.8% compared to its gross margin, suggesting potential for operational efficiency improvements.

• Trading on the OTC Other tier, which may present liquidity risks and limited investor access.
• High P/E ratio of 30.91, indicating elevated market expectations for future earnings growth.
• Dependence on the successful progression and commercialization of its R&D pipeline.
• Specific details regarding CEO background and track record are not publicly available in the provided data.

What Could Drive LBTSF Stock Higher?

LBTSF catalyst: Successful progression and positive clinical trial results for pipeline dermatological candidates, potentially leading to new drug applications.

• Regulatory approvals for new indications or novel treatments within its core dermatology segment, expanding market access.
• Strategic collaborations yielding new product candidates or accelerating development timelines for existing projects.
• Expansion into new geographic markets, particularly through successful commercialization of key products in untapped regions.
• Positive outcomes from regulatory decisions impacting the commercialization of its key products like Ilumetri and Klisyri.

What Are the Key Risks for LBTSF?

Rich valuation — a P/E of 30.91 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Liquidity risks associated with trading on the OTC Other tier, potentially hindering investor entry and exit.
• Intense competition within the specialty pharmaceutical and dermatology sectors, impacting market share and pricing power.
• Regulatory hurdles and delays in drug approvals, which could impact the commercialization timeline and revenue generation from pipeline assets.
• Dependence on the successful commercialization and market acceptance of its established key products, such as Ilumetri and Klisyri.
• Patent expirations for existing products, leading to generic competition and potential erosion of revenue streams.

What Are the Growth Opportunities for LBTSF?

• **Expansion in Dermatology Pipeline and Indications**: Almirall's ongoing research and development efforts present a significant growth opportunity by bringing new dermatological treatments to market or expanding existing product indications. For instance, advancing therapies for conditions like atopic dermatitis, psoriasis, and actinic keratosis, which have large patient populations, can drive substantial revenue growth. Successful clinical trials and regulatory approvals for pipeline candidates or new uses for established drugs like Ilumetri or Klisyri could unlock access to broader patient segments and market share, with the global dermatology market projected to reach significant valuations in the coming years.
• **Geographic Market Penetration**: While Almirall has a presence in Europe, the United States, and other international markets, there is substantial opportunity for deeper penetration into emerging markets and underserved regions. Expanding commercial operations and distribution networks in high-growth economies could significantly broaden the company's addressable market. This involves navigating diverse regulatory landscapes and establishing local partnerships, but successful entry into these markets could provide long-term revenue streams and diversify geographical risk, tapping into populations with increasing access to specialized healthcare.
• **Strategic Collaborations and Acquisitions**: The company's existing network of collaborations with entities like Tyris Therapeutics, BIOMAP, and Eli Lilly and Company serves as a foundation for future growth. Pursuing new strategic alliances or targeted acquisitions of innovative biotech firms can enhance Almirall's R&D capabilities, accelerate pipeline development, and bring novel technologies or compounds into its portfolio. These partnerships can provide access to cutting-edge research, reduce development risks, and expand therapeutic areas, positioning Almirall at the forefront of dermatological innovation and potentially opening new market segments.
• **Development of Orphan Drugs**: Almirall's focus on several orphan indications within dermatology represents a strategic growth avenue. Orphan drugs, designed to treat rare diseases, often benefit from expedited regulatory pathways, extended market exclusivity, and premium pricing due to the high unmet medical need and smaller patient populations. Successfully developing and commercializing therapies for these niche conditions can provide significant revenue contributions with less direct competition, offering a high-value, specialized market segment that aligns with Almirall's expertise in complex dermatological conditions.
• **Diversification within Non-Dermatology Therapeutic Areas**: Although dermatology is Almirall's core focus, its existing offerings in cardiovascular, musculoskeletal, respiratory, and neurological disorders, among others, present an opportunity for strategic diversification. While not the primary growth engine, selective investment and development within these established non-dermatology segments could leverage existing infrastructure and expertise. Expanding product lines or acquiring complementary assets in these areas could create additional revenue streams, reduce over-reliance on a single therapeutic area, and provide resilience against market fluctuations specific to dermatology.

What Threats Does LBTSF Face?

• Intense competition from larger pharmaceutical companies and specialized biotechs in the dermatology sector.
• Regulatory hurdles, delays in drug approvals, and potential for adverse regulatory decisions impacting product launches.
• Patent expirations for key products, leading to generic competition and erosion of market share.
• Potential for adverse drug events, product recalls, or litigation impacting reputation and financial performance.
• Economic downturns or changes in healthcare policy affecting pharmaceutical pricing and reimbursement.

What Are LBTSF's Competitive Advantages?

• Specialized focus and deep expertise in dermatology, fostering a strong brand reputation and clinical trust in this therapeutic area.
• Established portfolio of branded products with regulatory approvals and market presence, such as Ilumetri and Klisyri, providing consistent revenue streams.
• Extensive research and development capabilities, supported by numerous collaborations, enabling a robust pipeline of future drug candidates.
• Intellectual property protection and regulatory exclusivity for its key pharmaceutical assets, creating barriers to entry for competitors.
• Global commercial infrastructure and distribution networks across Europe, the US, and other international markets, facilitating broad market access.

What Does LBTSF Do?

Almirall, S.A. is a distinguished biopharmaceutical company with a rich history, originally established as Laboratorios Almirall, S.A. in 1943. The company adopted its current name, Almirall, S.A., in May 2009 and maintains its headquarters in Barcelona, Spain. Over decades, Almirall has evolved into a global player, specializing in the research, development, manufacturing, and commercialization of dermatology-focused pharmaceuticals. Its operational footprint extends across key markets including Europe, the United States, and various other international regions. The company's core mission revolves around providing innovative treatments for a comprehensive array of skin conditions. This includes prevalent disorders such as actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, and acne, alongside more specialized areas like oncodermatology and several orphan indications. Almirall's product portfolio is robust, featuring key brands like Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel, which address diverse dermatological needs. Beyond its primary focus on dermatology, Almirall strategically diversifies its offerings into other significant therapeutic areas. These include cardiovascular, musculoskeletal, respiratory, and neurological disorders, as well as alimentary tract and metabolic conditions, systemic anti-infectives, genitourinary system and sex hormones, immunostimulants, and systematic hormonal preparations. This broader therapeutic reach allows the company to cater to a wider patient population and market segments. Almirall actively fosters numerous collaborations and strategic alliances, which are integral to its innovation strategy and market expansion. These partnerships include notable entities such as Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. These alliances enhance its research and development capabilities, accelerate pipeline progression, and strengthen its competitive positioning within the global biopharmaceutical landscape.

What Products and Services Does LBTSF Offer?

• Research, develop, manufacture, and commercialize pharmaceuticals primarily focused on dermatology.
• Offer treatments for a wide range of skin conditions including actinic keratosis, atopic dermatitis, psoriasis, and acne.
• Provide specialized therapies for orphan dermatological indications.
• Maintain a portfolio of key products such as Ilumetri, Solaraze, Klisyri, and Sativex.
• Engage in strategic collaborations and alliances with academic institutions and other pharmaceutical companies for R&D.
• Extend its pharmaceutical offerings to other therapeutic areas including cardiovascular, respiratory, and neurological disorders.
• Operate and commercialize its products across Europe, the United States, and various international markets.
• Manage a workforce of 2026 employees dedicated to biopharmaceutical innovation and commercialization.

How Does LBTSF Make Money?

• Generates revenue through the sale of proprietary and licensed dermatological pharmaceuticals to healthcare providers and patients.
• Monetizes a diversified product portfolio that includes treatments for common skin conditions, specialized indications, and certain non-dermatological therapeutic areas.
• Invests heavily in research and development to discover, develop, and bring new drug candidates through clinical trials and regulatory approval.
• Leverages strategic partnerships and licensing agreements to expand its product pipeline, gain access to new technologies, and extend its market reach globally.
• Manages the entire value chain from drug discovery and manufacturing to commercialization and distribution across multiple international markets.

What Industry Does LBTSF Operate In?

Almirall, S.A. operates within the dynamic and highly competitive Drug Manufacturers - Specialty & Generic industry, with a distinct specialization in dermatology. The global dermatology market is experiencing significant growth, driven by increasing prevalence of skin conditions, rising aesthetic consciousness, and advancements in treatment modalities, including biologics and targeted therapies. Almirall is positioned as a focused player, leveraging its expertise in research, development, and commercialization of treatments for conditions ranging from common ailments like acne and psoriasis to complex orphan indications. The competitive landscape includes large pharmaceutical companies with diversified portfolios and smaller biotechs focused on specific dermatological niches. Almirall differentiates itself through its established product portfolio, extensive R&D pipeline, and strategic collaborations, aiming to capture market share by addressing unmet medical needs in skin health. The company's global reach across Europe, the US, and other international markets further solidifies its standing within this specialized segment.

Who Are LBTSF's Key Customers?

• Dermatologists, general practitioners, and other medical specialists who prescribe Almirall's pharmaceutical products.
• Patients suffering from various dermatological conditions, including chronic diseases like psoriasis and atopic dermatitis, as well as rare orphan indications.
• Hospitals, clinics, and pharmacies that procure and dispense Almirall's medications.
• Healthcare systems, insurance providers, and government agencies that facilitate access to and reimbursement for pharmaceutical treatments.

Almirall, S.A. (LBTSF) Valuation Context

Valued at $3.34B, LBTSF is classified as a mid-cap stock.

LBTSF Revenue & Earnings Trend

In Q2 FY2026, LBTSF generated $310.3M in top-line revenue, marking a sequential increase of 6.2%. The company recorded net income of $24.3M, with diluted EPS of $0.11. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, LBTSF averaged $0.08 in diluted EPS.

Company Profile

Almirall, S.A. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Barcelona, ES. The company is led by CEO Carlos Gallardo Piqué. LBTSF has traded publicly since 2012.

Return on equity for Almirall, S.A. stands at 3.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.2%, showing how much profit it generates from its asset base. LBTSF trades at a trailing price-to-earnings ratio of 30.91, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 7.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.32 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.2%, the inverse of the P/E and a quick read on earnings relative to price.

Almirall, S.A.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.30 places it in the safe zone, indicating low near-term bankruptcy risk.

LBTSF Financials

LBTSF Latest News

What Investors Ask About Almirall, S.A. (LBTSF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources